Oxford developed COVID vaccine, then scholars clashed over money | Curio
News and insights read out for you.
10,000+ audio articles. 50+ world-leading publications.

All in 1 subscription.

The Wall Street Journal logo

Oxford developed COVID vaccine, then scholars clashed over money

17 mins | Oct 30, 2020
story image

Behind the race for its distribution: on-campus clashes of ego and hastily made threats and promises. AstraZeneca eventually secured a deal to distribute Oxford's yet-to-be-approved vaccine. Why the British pharmaceutical? It could guarantee the university $100 million a year, bridging "Oxford’s history of nonprofit medical innovation and the pharmaceutical industry’s shareholder-driven motivations." In The Wall Street Journal, Jenny Strasburg and Stu Woo report on the remarkable events that transpired.

Get unlimited access free for 7 days, then $8.33/month (billed annually)
Get started